Literature DB >> 6286026

Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282).

J Davies.   

Abstract

1 The effects of a new muscle relaxant, 5-chloro-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282) have been examined on segmental reflexes and responses of single neurones in the spinal cord of the anaesthetized cat to stimulation of peripheral afferents, ventral roots, acetylcholine and various amino acids. Drugs were administered intravenously and/or iontophoretically.2 Polysynaptic reflexes were depressed in a dose-dependent manner by 0.01-0.1 mg/kg DS103-282 whereas monosynaptic reflexes were relatively insensitive to this agent.3 In studies on single dorsal horn neurones, iontophoretically and intravenously administered DS103-282 depressed synaptic excitatory responses, polysynaptic responses being much more sensitive to this agent than monosynaptic responses. In contrast (-)-baclofen preferentially reduced monosynaptic excitation.4 Doses or ejecting currents of DS103-282 which greatly depressed polysynaptic excitatory responses also reduced spontaneous firing of neurones, but either had no effect or minimal depressant effects on responses to iotophoretically administered excitant amino acids. Acetylcholine-induced excitation of Renshaw cells was depressed by iontophoretically (but not intravenously) administered DS103-282, although ventral root-evoked responses of these cells were insensitive to this agent.5 Inhibition of spinal neurones by stimulation of peripheral nerves or by iontophoresis of gamma-aminobutyric acid or glycine was unaffected by DS103-282.6 These results indicate that DS103-282 preferentially depresses peripherally evoked polysynaptic excitation of spinal neurones probably by an action on the terminals of excitatory interneurones.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286026      PMCID: PMC2071800          DOI: 10.1111/j.1476-5381.1982.tb09242.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

Review 1.  Amino acid transmitters in the mammalian central nervous system.

Authors:  D R Curtis; G A Johnston
Journal:  Ergeb Physiol       Date:  1974

2.  Visual response characteristics of neurons in nucleus of basal optic root of pigeons.

Authors:  B Morgan; B J Frost
Journal:  Exp Brain Res       Date:  1981       Impact factor: 1.972

3.  The synaptic excitation of Renshaw cells.

Authors:  D R Curtis; R W Ryall
Journal:  Exp Brain Res       Date:  1966       Impact factor: 1.972

4.  The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent.

Authors:  A C Sayers; H R Bürki; E Eichenberger
Journal:  Arzneimittelforschung       Date:  1980

5.  Selective depression of synaptic excitation in cat spinal neurones by baclofen: an iontophoretic study.

Authors:  J Davies
Journal:  Br J Pharmacol       Date:  1981-02       Impact factor: 8.739

6.  Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.

Authors:  N Hassan; D L McLellan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-12       Impact factor: 10.154

  6 in total
  11 in total

1.  Spinal interneurone depression by DS103-282.

Authors:  D R Curtis; J D Leah; M J Peet
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

2.  Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia.

Authors:  T Fuchigami; O Kakinohana; M P Hefferan; N Lukacova; S Marsala; O Platoshyn; K Sugahara; T L Yaksh; M Marsala
Journal:  Neuroscience       Date:  2011-08-16       Impact factor: 3.590

Review 3.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

Authors:  M Emre; G C Leslie; C Muir; N J Part; R Pokorny; R C Roberts
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 5.  Cervical myofascial pain and headache.

Authors:  Joanne Borg-Stein
Journal:  Curr Pain Headache Rep       Date:  2002-08

6.  Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Authors:  Herbert R Henney; Michael Chez
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

7.  Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord.

Authors:  J Davies; S E Johnston
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

8.  Role of excitatory amino acid receptors in mono- and polysynaptic excitation in the cat spinal cord.

Authors:  J Davies; J C Watkins
Journal:  Exp Brain Res       Date:  1983       Impact factor: 1.972

9.  Modulation of the transmission in group II heteronymous pathways by tizanidine in spastic hemiplegic patients.

Authors:  E Maupas; P Marque; C F Roques; M Simonetta-Moreau
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

10.  Non-cholinergic synaptic excitation in neostriatum: pharmacological evidence for mediation by a glutamate-like transmitter.

Authors:  G E Cordingley; F F Weight
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.